Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease

BACKGROUND: Sorafenib is the recommended treatment for advanced hepatocellular carcinoma (HCC), but transarterial chemoembolization (TACE) is performed in individual cases with limited extrahepatic spread. The aim of this study was to compare the outcome of patients with HCC and extrahepatic disease...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :United European Gastroenterol J
Главные авторы: Kirstein, Martha M, Voigtländer, Torsten, Schweitzer, Nora, Hinrichs, Jan B, Marquardt, Jens, Wörns, Marcus-Alexander, Kloeckner, Roman, Fründt, Thorben W, Ittrich, Harald, Wacker, Frank, Rodt, Thomas, Manns, Michael P, Wege, Henning, Weinmann, Arndt, Vogel, Arndt
Формат: Artigo
Язык:Inglês
Опубликовано: SAGE Publications 2018
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833223/
https://ncbi.nlm.nih.gov/pubmed/29511553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2050640617716597
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы